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Abstract 
 
Three PEGylated derivatives of 1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-
4,7,10-triacetic acid) (DOTA-AHA) with different molecular weights were prepared and 
characterized. Their Gd(III) chelates were studied in aqueous solution using variable-
temperature 1H nuclear magnetic relaxation dispersion (NMRD) and 17ONMR 
spectroscopy in view of the determination of their relaxivity and the parameters that 
govern it. The relaxivity  varied from 5.1 to 6.5 mM-1.s-1 (37 ºC and 60 MHz) with the 
increasing molecular weight of the PEG chain, being slightly higher than that of the parent 
chelate Gd(DOTA-AHA), due to a small contribution of a slow global rotation of the 
complexes. 
A variable temperature 1H NMR study of several Ln(III) chelates of DOTA-
A(PEG750)HA allowed the determination of the isomeric M/m ratio (M = square 
antiprismatic isomer and m = twisted square antiprismatic isomer, the latter presenting a 
much faster water exchange) which for the Gd(III) chelate was estimated in circa 1:0.2, 
very close to that of [Gd(DOTA)]-. This explains why the PEGylated Gd(III) chelate has 
a water rate exchange similar to that of [Gd(DOTA)]-. The predominance of the M isomer 
is a consequence of the bulky PEG moiety which does not favor the stabilization of the m 
isomer in sterically crowded systems at the substituent site, contrary to what happens with 
less packed asymmetrical DOTA-type chelates with substitution in one of the four acetate 
C(α) atoms. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Magnetic resonance imaging (MRI) is one of the most powerful and useful techniques in 
medicine for soft tissue imaging. Images are generated by spatially encoding the signal 
coming from the water hydrogen nuclei of the tissues through the application of time-
varying, linear magnetic field gradients and pulses of radiofrequencies.[1] The quality of 
a MRI scan depends on intrinsic properties of the biological tissues such as the density 
(H) of the hydrogen nuclei, the blood flow and the hydrogen nuclei relaxation times (T1 
and T2). In circa 40% of MRI scans there is the need of paramagnetic contrast agents 
(CAs) which shorten the hydrogen nuclei relaxation times of neighboring water 
molecules, increasing the signal intensity on T1 weighted images and decreasing it on T2 
weighted images, enhancing thus the contrast between the body tissues.[2] Gd(III) is 
particularly suitable for the purpose of contrast enhancement in T1 weighted images, due 
to its high magnetic moment and long electronic relaxation time, which results in a strong 
dipolar interaction with the hydrogen nuclei.[3] 
The vast majority of the approved CAs are Gd(III) chelates based both on macrocyclic 
tetraazapolyaminocarboxylate chelators (ex: Dotarem®, Prohance® or Gadovist®) and 
open-chain polyaminocarboxylate chelators (ex: Magnevist®, Omniscan® or 
Multihance®). These low molecular weight extracellular fluid CAs rapidly equilibrate 
between the intravascular and interstitial spaces.[4] This equilibrium decreases the 
effective concentration of Gd(III) within the blood vessels and distributes gadolinium into 
the interstitial tissues where it may increase background noise.[5] 
The effectiveness of any contrast agent is measured by its relaxivity (r), which is the 
enhancement of the water protons relaxation rate imposed by a 1 mM concentration of 
Gd(III) chelate.[6] There are several approaches to increase the relaxivity through the 
optimization of its molecular parameters. The rotational correlation time (R), water 
exchange rate (kex) and electron spin relaxation times (Te) are the most important 
parameters ruling relaxivity. Because Te is mainly dependent on the metal ion it is not 
easily changeable while the other two parameters can be more or less efficiently 
optimized.[6] To increase the rotational correlation time of  the Gd(III) complexes seems 
to be the most straightforward choice and this has been achieved through several 
strategies: formation of multinuclear assemblies, either through covalently bound chelates 
(multimeric structures,[7] linear polymeric structures,[7d, 8] spherical dendrimers[9]) or 
through non-covalently bound chelates (micelles,[10] liposomes[10c, 11]). All these 
multinuclear assemblies of Gd(III) chelates constitute macromolecular CAs which 
compared to small molecule CAs, besides an enhanced relaxivity, present extended 
retention in the blood circulation presenting thus great potential in angiography, cancer 
imaging, kidney imaging, liver imaging, lymphatic imaging, noninvasive visualization of 
drug delivery, etc.[12] 
The insertion of PEG (polyethylene glycol) units in the chelates or in their multinuclear 
assemblies has been exploited over the years considering the advantages that PEGylation 
can offer including prolonged retention time in circulation, increased excretion, decreased 
accumulation in the organs and increased uptake in tumors. The long-chain amphiphilic 
PEG moieties are inert and can increase the solubility of complexes in water[13] and 
prolong circulating half-life of proteins, polymers and small molecules.[14] PEGylation 
has also been shown to reduce immunogenicity.[15] Due to these properties, the 
incorporation of PEG moieties onto radiolabeled DOTA-based bioconjugates in order to 
reduce liver uptake and increase tumor accumulation has been reported over the years.[16] 
In the search for new MRI CAs, the insertion of PEG units in gadolinium containing 
systems has been exploited in different manners, from single chelates[17] to 
copolymeric[8a, 16b, 18] and dendrimeric chelates.[19] The present work aimed at verifying 
the influence of the introduction of PEG moieties on the relaxivity of Gd(III) chelates of 
asymmetrical DOTA-based ligands. For this purpose three derivatives of DOTA-AHA 
(1,4,7,10-tetraazacyclododecane-1-[(6-amino)hexanoic]-4,7,10-triacetic acid) with 
grafted PEG chains with distinct molar masses (750, 550 and 350 g.mol-1; respectively 
L1, L2 and L3 in Figure 1) were synthesized and characterized. The Gd(III) chelates of 
the three DOTA-A(PEG)HA ligands were studied by 1H NMRD and 17ONMR and for a 
better understanding of the PEG pendant groups influence on the relaxometric properties, 
1H NMR studies of several paramagnetic lanthanide chelates of DOTA-A(PEG750)HA 
were also conducted. 
 
 Figure 1. DOTA-A(PEG)HA (L1, L2, L3). 
 
Results and Discussion 
 
Synthesis 
The PEGylation of DOTA-AHA was accomplished using activated PEG moieties with 
succinic anhydride (scheme 1, compounds 2-4) with the pro-ligand DOTA-AHA (scheme 
1, compound 1). The DOTA-AHA pro-chelator was prepared according to the 
methodology described recently.[20] After deprotection, the PEGylated ligands 1,4,7,10-
tetraazacyclododecane-1-[6-amino(succinate-PEG750-OMe)hexanoic)]-4,7,10-triacetic 
acid (L1 = DOTA-A(PEG750)HA), 1,4,7,10-tetraazacyclododecane-1-[6-
amino(succinate-PEG550-OMe)hexanoic]-4,7,10-triacetic acid (L2 = DOTA-
A(PEG550)HA) and 1,4,7,10-tetraazacyclododecane-1-[6-amino(succinate-PEG350-
OMe)hexanoic]-4,7,10-triacetic acid (L3 = DOTA-A(PEG350)HA) were isolated in good 
yields. 
 
 Scheme 1. Synthesis of DOTA-AHA PEGylated conjugates. A) succinic anhydride, CHCl3, H2SO4 (95%); 
b) DIPEA, HATU, HOBt, MeCN; c) TFA, DCM. 
 
1H NMRD and 17O NMR relaxometric studies 
To obtain the parameters determining the relaxivity, all PEGylated Gd(III) chelates have 
been studied by 1H relaxometry (Figure 2) and the chelate [Gd(L2)]- has also been studied 
by 17O NMR relaxation and chemical shifts measurements (Figure 3). The results of a 
combined analysis using the Solomon-Bloembergen-Morgan model of the latter chelate 
show that water exchange rate (Table 1) is not influenced by PEGylation in relation to 
Gd(DOTA), being actually slightly higher than that of this chelate (298kex = 4.1x10
6 s-1).[21] 
These results are in contrast with what has been previously reported for the PEGylated 
hetero-tripodal hydroxypyridonate (HOPO) gadolinium complexes, since the coupling of 
PEG moieties lead to a decrease in the kex values in relation to HOPO complexes without 
PEG.[17a, 17c] In this case, the authors ascribed such effect to the formation of hydrogen 
bonds with water molecules which induce partial displacement of the inner sphere water 
molecules; the strength of these bonds being strong enough for the reduction of the 
number of water molecules in the inner sphere (q) from 2 (non-PEGylated chelate) to 1 
(PEGylated chelates).[17a, 17c] Fixing a long chain like PEG in the more rigid [Gd(DOTA-
A(PEG)HA)]- has only a minor influence on its structure (see M/m ratio in next section), 
and consequently no such effect on the water molecule residence time is observed. We 
therefore fixed the water exchange rate constants in the analysis of the relaxivity data to 
the values of [Gd(L2)]- (Table 1). 
  
Figure 2. 1H NMRD profile of [Gd(L1)]- (■, □; red), [Gd(L2)]- (, ○; black) and [Gd(L3)]- (▲, Δ; blue) 
chelates at 25 ºC (filled symbols) and 37 °C (empty symbols). The lines represent the best fit of the data 
resulted from simultaneous fitting based on SBM equations. 
 
 
Figure 3. Reduced 17O transverse (□) and longitudinal (○) relaxation rates and reduced chemical shifts (◊) 
(B = 9.4 T) for the [Gd(L2)]- chelate. The lines represent the best simulation fit of experimental data. 
 
 
 
 
 
The 1H NMRD profiles of the PEGylated compounds (Figure 2) show that the relaxivity 
reaches its maximum at 60 MHz. PEGylation of the chelates results in improved 
relaxivity values in relation to its parent chelate Gd(DOTA-AHA)[20] at all applied 
frequencies (Gd(DOTA-A(PEG750)HA): 38% augmentation in r1 at 37 ºC and 60 MHz). 
If one compares relaxivity with that of Gd(DOTA) the increase is 110%.[21] This 
improvement is in contrast to what has been observed on PEGylation of DTPA-BMA 
based complexes.[8a] This difference can probably be attributed to the 10 times slower 
water exchange on [Gd(DTPA-BA)-PEG] which is limiting relaxivity in that case. 
 
Table 1. Relaxometric parameters for [Gd(L1)]-, [Gd(L2)]- and [Gd(L3)]- The [Gd(L2)]- parameters were 
obtained from the simultaneous analysis of 17O NMR and 1H NMRD data, using the Solomon-
Bloembergen-Morgan approach(a)(b). 
Parameter [GdL1]- [GdL2]- [GdL3]- 
H‡ (kJ.mol-1) 47 47 ± 5.4 47 
298kex (106 s-1) 5.0 5.1  ± 0.8 5.0 
A/ћ (106 rad.s-1)  -2.9 ± 0.2(c)  
COS  0.1   
298g (ps) > 40000 10000 9000 ± 7000 
298l (ps) 235 ± 9 231 ± 7 212 ± 4 
S2 0.05 ± 0.01 0.041 ± 0.006 0.02 ± 0.003 
298v (ps) 13 ± 3 16 ± 2 22 ± 3 
(a) The italicized values of parameters in the table were calculated from 17O NMR measurements of 
[Gd(L2)]- and kept as constant parameters for the NMRD fitting of the other two [Gd(L1)]- and [Gd(L3)]- 
compounds. 
(b) Other parameters fixed in the fitting procedure are: 2 /1020 = 1.0 s-2, rGdO = 2.5 Å, rGdH = 3.1 Å, aGdH = 
3.6 Å, EGdH = 20 kJ.mol-1 and q = 1. 
(c) The unusually small value of A/ћ is due to experimental 17O 1/T2r data and 1/T1e which is mainly defined 
by 1H NMRD. 
 
Through the analysis of the 1H NMRD profiles, it is also noticeable that the relaxivity is 
related to the PEG molecular weight. [Gd(L1)]-(r1 = 6.5 mM
-1.s-1at 37 ºC and r1 = 8.0 
mM-1.s-1at 25 ºC and 60 MHz), which is the chelate with an heavier PEG moiety, has 
higher relaxivity in comparison to [Gd(L2)]-(r1 = 5.9 mM
-1.s-1at 37 ºC and r1 = 7.8 mM
-
1.s-1at 25 ºC and 60 MHz), which in turn has a higher value than that of the smaller chelate 
[Gd(L3)]- (r1 = 5.1 mM
-1.s-1at 37 ºC and r1 = 6.8 mM
-1.s-1at 25 ºC and 60 MHz). This 
trend is most perceptible at frequencies where the rotational correlation time has more 
influence on the relaxivity values (between 40 and 100 MHz). 
The NMRD profiles (Figure 2) could only be fitted using a Lipari-Szabo model free 
approach taking into account internal rotational motion.[22] All three compounds show a 
very long g corresponding to the global rotation of the complexes and a much shorter l 
describing the actual rotation of the Gd-H vectors (Table 1).The model free order 
parameter S2 is for all compounds very small with values from 0.05 to 0.02. This shows 
that the rotation of the Gd-H vector is largely dominated by the short local correlation 
time which is for all compounds between 210 to 235 ps. The global rotation of the ligands 
with longer PEG chains [Gd(L1)]- and [Gd(L2)]- are slow (10 ns) and even the compound 
with the shortest PEG chain has a g ≈ 9 ns. A consequence of the small values for S2is 
the small relaxivity hump shown for all three compounds. However, even for such a small 
order parameter, the contribution of the global motion leads to a relaxivity increase of ≈ 
20% at 60 MHz (Figure 4). At high magnetic fields (B0 > 3 T) the slow global motion has 
no influence on the relaxivities. 
 
 
Figure 4. 1H NMRD profile of [Gd(L2)]- at 25 ºC (filled symbols) and 37 °C (empty symbols). The lines 
represent the best fit of the data (S2 = 0.04); the dashed lines are calculated using the same parameters 
except S2 set to zero. 
 
 
 
 
 
 
1H NMR studies of paramagnetic lanthanide L1 chelates 
The trivalent lanthanide complexes of DOTA-based ligands exhibit a variety of 
conformational and coordination isomers which may display dynamic behavior on the 
NMR timescale.[23] The isomers of their Gd(III) chelates have been found to have 
different relaxivity properties.[24] Considering this, some 1H NMR studies have been 
performed with some paramagnetic lanthanide L1 chelates. 
1H NMR is a valuable technique for the solution study of the isomers of the Ln(III) 
complexes of DOTA and its derivatives.[23a, 23b] The high symmetry of DOTA leads to the 
existence of two isomers of the [Ln(DOTA)]- chelates in solution, with square 
antiprismatic (M) and twisted square antiprismatic (m) geometries.[25] These isomers have 
the same [3.3.3.3] square conformation with fourfold symmetry of the 
tetraazacyclododecane ring, where all its ethylenic groups adopt a  or  conformation, 
thus leading to conformations of clockwise or counterclockwise helicity,  or . 
They only differ on the layout of the four acetate pendant arms, resulting from rotations 
around the N-CH2-CO2 bonds, with either a clockwise () or counterclockwise () 
helicity. These lead to the two diastereoisomers existing in solution (m and M), with 
separate NMR resonances, each of which is an enantiomer pair: the square antiprismatic 
(M) geometry results from the opposite helicity of the tetraaza ring and the acetate arms 
(() or ()), while the twisted antiprismatic (m) geometry has the same ring 
and acetate helicity (() or ()). Thus M and m differ in the value and sign of 
the twist angle  between the diagonals of the parallel squares formed by four N-atoms 
and the four carboxylate O-atoms in the coordination polyhedron of the DOTA chelates 
(typical values of  ≈ +35º and  ≈ -15º, respectively, found from crystallographic 
structures).[23a] The isomer M shows a wider paramagnetic shift range than m throughout 
the lanthanide series. The isomer m is dominant relative to M for the early Ln(III) chelates 
(Ln = La – Pr), but M becomes dominant for the smaller ions (Ln = Eu – Lu).[23c] 
Similarly to the ligand DOTASA,[26] L1 is an asymmetrical derivative of DOTA, with 
one of the four acetate C() atoms substituted. In the case of L1 the asymmetry is 
introduced through the inclusion of an amide-PEG-bearing group, leading to the existence 
of a chiral center in the ligand and a site of asymmetry in the complexes which double 
the number of possible isomeric species. As we have obtained the ligand L1 as a racemic 
mixture of the (R) and (S) enantiomers, the complete identification of all possible 
stereoisomers requires identification of the configuration (R) of the chiral C-atom of the 
ligand, together with the four arrangements of the ligand itself in the complex described 
above for DOTA complexes. Due to this, in solution there can be up to eight stereoisomers 
of [Ln(L1)]- of the type W-X (W = I or (S); X = M (() or ()) or m (() 
or ()), consistent with four enantiomer pairs: I-M, I-m, (S)-M and (S)-m. 
Considering this, up to four sets of 1H NMR signals are to be expected from these 
enantiomer pairs. The lack of C4 symmetry removes the signal degeneracy found in the 
NMR spectra of [Ln(DOTA)]- complexes and leads to a large number of resonances for 
each isomer in the 1H NMR spectra. 
The special properties of the paramagnetic Pr(III), Nd(III), Sm(III) and Eu(III) chelates 
of L1 were investigated by 1H NMR at three different temperatures (25 ºC, 40 ºC and 60 
ºC), showing a large number of partially overlapping resonances covering paramagnetic 
shift ranges in accordance with those observed for the corresponding DOTA chelates.[25b, 
25d] Previous 1H NMR studies with the symmetrical [Ln(DOTA)]- chelates, and with a 
variety of lanthanide derivatives of DOTA,[23a] have demonstrated that the two 
diastereoisomers m and M are present in solution, with a relative proportion that is a 
function of the lanthanide ion, temperature, solvent and the steric crowding of the 
chelate.[23a, 23c] Steric crowding favors the m isomer and this has been demonstrated by 
comparing the populations of both isomers of lanthanide(III) complexes of DOTA and 
DOTA analogs.[27] 
The two isomers are characterized by different dipolar shifts, with complexes of the M 
form possessing the larger paramagnetic shift for a given ligand resonance. Through the 
analysis of the obtained 1H NMR spectra, the M/m isomer ratio could be determined for 
several complexes. For this purpose it is particularly useful to observe the resonance in 
the most-shifted axial ring proton, ax1, which is well separated from the others.
[23a, 23c, 25] 
For example, in the case of [Ln(DOTA)]- complexes this resonance is observed at circa 
+30-50 ppm and circa +150-160 ppm for the M isomers, while for the corresponding m 
forms, the axial ring protons ax1 has resonances at lower frequencies, at circa +10-30 
ppm and circa +90-100 ppm for Eu(III) and Yb (III) complexes, respectively.[23a, 28] 
Similarly to what has been previously found in asymmetric DOTA-based complexes, the 
ax1 protons of most of the studied Ln(III) complexes of L1 originated two sets of well 
separated signals, which could be assigned to the isomers M and m, as shown in Figures 
5 and 6. The chemical shifts of the axial protons in the chelates of Pr(III), Nd(III) and 
Sm(III) are negative while in the case of Eu(III) they are positive, according to the 
Bleaney constants, which are negative for the first cations and positive for the latter.[29] 
Integration of those signals afforded the isomer ratios M/m, as shown in Table 2. As 
expected, isomer m is dominant for the early lanthanide chelate (praseodymium), 
decreasing its fraction along the lanthanide series, as the ionic radius of the Ln(III) ions 
decreases.[23a, 23c] Density functional theory (DFT) calculations on DOTA-like complexes 
showed that the stabilization of the M isomer on proceeding to the right across the 
lanthanide series is the result of an increased binding energy of the ligand to the metal for 
this isomer as the charge density of the lanthanide ion increases.[27b] 
It is known that m isomers of lanthanide macrocyclic DOTA-type chelates have about 50 
times faster water exchange (kex) than M isomers.
[30] For [Gd(DOTA)]- an M/m isomer 
ratio of circa 6:1 was calculated by interpolation of the ratio for the Eu(III) and Tb(III) 
chelates, while for [Gd(DOTASA)]2- an isomer ratio of 1:1 was obtained, accounting for 
a 50% increase in the water exchange rate of the latter chelate.[26] The comparison of the 
observed M/m ratio for the present PEGylated chelate shows that despite the preservation 
of the trend in the M/m ratio just described, the dominance of the m isomer for the 
complexes of the early Ln(III) ions is not so significant as in other cases.[26, 28b] By analogy 
with the ratio obtained for other Gd(III) chelates, which show to be close to that of the 
corresponding Eu(III) chelates, a value of circa 1:0.2 can be estimated for our Gd(III) 
chelate, very close to that of [Gd(DOTA)]-. This might be a consequence of the PEG 
moiety, which is a bulky substituent that does not favor the stabilization of the m form in 
sterically crowded systems [28c] as it happens in less bulky systems, such as in DOTASA 
chelates.[31] The predominance of the M isomer could explain why [Gd(L1)]- has a similar 
water exchange rate to [Gd(DOTA)]-. Exchange between the m and M isomers is 
demonstrated by the broadening at 40 ºC (Figure 6) and further signal collapse of the 
resonances of both isomers observed at 60 ºC.[25c] 
 
Table 2. 1H NMR chemical shifts (ppm) of the ax1 protons of the paramagnetic lanthanide L1 chelates in 
M and m isomeric forms at 25 °C and pH=7. 
Metal Ion M Isomer m Isomer M/m Ratio 
Pr -47.16; -40.31 -31.55; -28.81; -24.81; -23.87 1 : 1.5 
Nd -24.38; -21.21 -11.99; -10.31; -8.24; -7.80 1 : 1 
Sm -3.53; -3.04; -2.49 Not Assigned --- 
Eu 33.16; 36.83 13.34; 14.01; 16.77; 18.19 1 : 0.25 
 
 Figure 5. 1H NMR resonances of the ax1 protons of the M and m isomers of the paramagnetic lanthanide 
L1 chelates at pH=7.1 and 25 °C. a) Ln = Pr; b) Ln = Nd; c) Ln = Sm; d) Ln = Eu. 
 Figure 6. 1H NMR resonances of the ax1 protons of the M and m isomers of the paramagnetic lanthanide 
L1 chelates at pH=7.1 and 40 °C. a) Ln = Pr; b) Ln = Nd; c) Ln = Sm; d) Ln = Eu. 
  
Conclusion 
 
Using a synthetic methodology previously described for the chelator DOTA-AHA, it was 
possible to prepare three PEGylated derivatives [DOTA-A(PEG)HA]. The Gd(III) 
chelates of these ligands were designed as potential MRI contrast agents, taking into 
consideration an enhancement of the relaxivity thanks to longer rotational correlation 
times and the fact that PEG moieties may also act as pharmacokinetic modifiers, including 
a prolongation of their circulating time, with concomitant possibility of using them in 
angiography. 
The three PEGylated Gd(III) chelates were studied by 1H relaxometry and 17O NMR was 
used for the characterization of [Gd(L2)]-, allowing the determination of the parameters 
that govern their relaxivities.The PEGylation of Gd(DOTA-AHA) resulted in a relaxivity 
increase, which is specially noteworthy considering that in the past other authors have 
considered the PEGylation of paramagnetic chelates a not so efficient way of increasing 
relaxivity. Our results can be explained taking into consideration that a) PEGylation did 
not decrease the number of bound water molecules; b) PEGylation did not affect 
negatively the water exchange rate; c) the rotational motion is dominated by fast local 
motion with a small contribution due to a slow global reorientation.    
1H NMR studies of paramagnetic [Ln(L1)]- chelates were conducted, putting in evidence 
the ratio of the square antiprismatic (M) and the twisted square antiprismatic isomers (m) 
in solution. Contrary to other DOTA-type chelates asymmetrically substituted in one of 
the four acetate C(α) atoms, which in some cases can increase the proportion of the m 
isomer which displays the faster water exchange rate, the inclusion of PEG chains in the 
chelates did not alter the isomeric M/m ratio proportion, which in this regard is similar to 
that of [Gd(DOTA)]-. 
 
 
 
 
 
 
  
Experimental 
 
Chemicals and Materials 
Analytical grade solvents were used and dried by the usual methods when was needed. 
Analytical grade reagents were purchased from Sigma-Aldrich, Acros, Bachem, Merck, 
Chematech and used without further purification. 17O-enriched water was purchased from 
IsoTrade GmbH (Mönchengladbach, Germany). 
The reactions were monitored by thin layer chromatography (TLC) on glass plates coated 
with silica gel 60 F254 (Whatman) and detection was made by examination under UV light 
(240 nm), by adsorption of iodine vapor and/or by spraying with ninhydrin. 
Chromatographic separations were performed on silica gel 60 (Whatman 230-240 Mesh). 
 
Instruments 
The 1H and 13C NMR spectra (assigned by DEPT, HSQC and HMBC techniques) were 
recorded on a Bruker Avance III 400 spectrometer, operating at 400.13 MHz and 100.62 
MHz, for 1H and 13C NMR respectively. The 1H NMR spectra of DOTA-A(PEG750)HA 
paramagnetic lanthanide complexes were recorded on a Varian Unity Plus 300, operating 
at 299.938 MHz. The chemical shifts () are reported in ppm, relative to TMS 
(tetramethylsilane) for CDCl3 solvent (
1H, =7.26; 13C, =77.16) or DMSO solvent (1H, 
=2.50; 13C, =39.52), and relative to TSP (3-(trimethylsilyl)propionic-2,2,3,3-d4 acid 
sodium salt) for D2O solvent (
1H, =4.79).[32] The pH measurements were performed on 
a pH meter Crimson micro TT 2050 with an electrode Mettler Toledo InLab 422. 
The proton longitudinal relaxation rates (1/T1) for the water nuclear magnetic relaxation 
dispersion profiles (NMRD) were measured using the following equipment: Bruker 
minispecs mq20 0.47 T (1H Larmor frequency: 20 MHz); mq30 0.70 T (30 MHz); mq40 
0.94 T (40 MHz); and mq60 1.41 T (60 MHz); Bruker Avance console connected to 
2.35 T (100 MHz) and 4.7 T (200 MHz) cryomagnets and Bruker Avance II 9.4 T 
(400 MHz). The temperature was controlled either by a thermostated gas flow 
(cryomagnets) or by pumping a thermostated liquid trough the probe (minispecs). All 
temperatures were measured by substitution technique.[33] The variable-temperature 17O 
measurements were performed on a Bruker Avance II 9.4 T (17O Larmor frequency: 
54.3 MHz) spectrometer, equipped with a Bruker BVT3000 temperature control unit and 
a Bruker BCU05 cooling unit. The susceptibility measurements were performed on a 
Bruker Avance 400 spectrometer, also equipped with a BVT-3000 temperature control 
unit. 
 
Synthesis 
succinate-PEG750-OMe, 2 
HO-PEG750-OMe (4.2 g, 5.4 mmol) was dissolved in dry CHCl3 (20 mL) and to this 
solution succinic anhydride (554 mg, 5.3 mmol) and a catalytic amount of sulfuric acid 
(95%) were added. The solution was stirred for 6 hours at reflux temperature and 
concentrated under reduced pressure to afford compound 2 (4.7 g) as a colorless oil. The 
product was used without further purification. 1H NMR (400 MHz, CDCl3, TMS) : 2.61-
2.71 (4H, m, - and -CH2 succinate), 3.38 (3H, s, OMe), 3.54-3.56 (2H, m, -CH2 
PEG), 3.59-3.72 (nH, m, -CH2 PEG + nPEG), 4.24-4.27 (2H, m, -CH2 PEG) ppm. 13C 
NMR (100 MHz, CDCl3, TMS) :  28.95 (-CH2 succinate), 29.41 (-CH2 succinate), 
58.98 (OMe), 63.80 (-CH2 PEG), 68.93 (-CH2 PEG), 70.46, 70.48, 70.50 (nPEG), 
71.88 (-CH2 PEG), 172.02 (C=O), 174.36 (C=O) ppm. LRMS (ESI+) – m/z: calculated 
for: n = 17 – C41H80O22 (MH+) 925.52; found 925.75 (MH+); n = 16 – C39H76O21 (MH+) 
881.50; found 881.75, (MH+); n = 15 – C37H72O20 (MH+) 837.47; found 837.67, (MH+); 
n = 14 – C35H68O19 (MH+) 793.44; found 793.69, (MH+); n = 13 – C33H64O18 (MH+) 
749.42; found 749.70 (MH+). 
 
succinate-PEG550-OMe, 3 
Using a similar procedure to that previously described for compound 2, but using HO-
PEG550-OMe (2.2 g, 3.7 mmol) it was possible to obtain compound 3 (2.5 g) as a colorless 
oil. The product was used without further purification.1H NMR (400 MHz, DMSO, TMS) 
: 2.43-2.58 (4H, m, - and -CH2 succinate), 3.23 (3H, s, OMe), 3.39-3.43 (2H, m, -
CH2 PEG), 3.46-3.54 (nH, m, nPEG), 3.58 (2H, t, J=4.8 Hz, -CH2 PEG), 4.11 (2H, t, 
J=4.6 Hz, -CH2 PEG) ppm. 13C NMR (100 MHz, DMSO, TMS) :  28.61, 28.64 (- 
and -CH2 succinate), 58.03 (OMe), 63.44 (-CH2 PEG), 68.22 (-CH2 PEG), 69.57, 
69.72, 69.77 (nPEG), 71.27 (-CH2 PEG), 171.94 (C=O), 173.35 (C=O) ppm. LRMS 
(ESI+) – m/z: calculated for: n = 13 – C33H64O18 (MH+) 749.42; found 749.83, (MH+); n 
= 12 – C31H60O17 (MH+) 705.39; found 705.50, (MH+); n = 11 – C29H56O16 (MH+) 661.36; 
found 661.42, (MH+); n = 10 – C27H52O15 (MH+) 617.34; found 317.42, (MH+); n = 9 – 
C25H48O14 (MH
+) 573.31; found 573.52 (MH+). 
succinate-PEG350-OMe, 4 
Using a similar procedure to that previously described for compound 2, but using HO-
PEG350-OMe (4.3 g, 12.2 mmol) it was possible to obtain compound 4 (5.4 g) as a 
colorless oil. The product was used without further purification. 1H NMR (400 MHz, 
DMSO, TMS) : 2.43-2.59 (4H, m, -CH2 succinate + -CH2 succinate), 3.23 (3H, s, 
OMe), 3.39-3.44 (2H, m, -CH2 PEG), 3.48-3.55 (nH, m, nPEG), 3.59 (2H, t, J=4.8 Hz, 
-CH2 PEG), 4.11 (2H, t, J=4.6 Hz, -CH2 PEG) ppm. 13C NMR (100 MHz, DMSO, 
TMS) :  28.57, 28.64 (-CH2 succinate) + (-CH2 succinate), 58.02 (OMe), 63.44 (-
CH2 PEG), 68.23 (-CH2 PEG), 69.56, 69.72, 69.77 (nPEG), 71.27 (-CH2 PEG), 171.89 
(C=O), 173.34 (C=O) ppm. LRMS (ESI+): calculated for: n = 9 – C25H48O14 (MH+) 
573.31; found 573.70 (MH+); n = 8 – C23H44O13 (MH+) 529.29; found 529.36 (MH+); n 
= 7 – C21H40O12 (MH+) 485.26; found 485.63 (MH+); n = 6 – C19H36O11 (MH+) 441.23; 
found 441.92 (MH+); n = 5 – C17H32O10 (MH+) 397.21; found 397.83 (MH+). 
 
DO3A(t-Bu)-A(succinate-PEG750-OMe)HA(Be), 5 
DO3A(t-Bu)-AHA(Be) (370 mg, 457 mol) was dissolved in dry MeCN (30 mL) and to 
this solution, succinate-PEG750-OMe (544 mg, 640 mol), DIPEA (80 L, 457 mol), 
HOBt (104 mg, 767 mol) and HATU (292 mg, 767 mol) were added. The solution was 
stirred for 48 hours at room temperature and more HOBt (104 mg, 767 mol) and HATU 
(292 mg, 767 mol) were added. The solution was stirred for more 48 hours at room 
temperature and concentrated under reduced pressure to give a yellow oil. The oil was 
dissolved in ethyl acetate (75 mL), and the organic phase was washed with KHSO4 1M 
(2 x 45 mL), NaHCO3 1M (2 x 45 mL) and brine (2 x 45 mL). The organic phases were 
combined, dried with anhydrous MgSO4 and concentrated under reduced pressure to 
afford compound 5 (485 mg, 65 %) as a yellow solid.  1H NMR (400 MHz, CDCl3, TMS) 
: 1.15-1.50 (31H, mb, -CH2 + -CH2 + CH3t-Bu), 1.62-1.81 (2H, m, -CH2), 1.97-3.34 
(28H, m, CH2 cyclen + -CH2 + CH2COR + -CH2 succinate + -CH2 succinate), 3.36 
(3H, s, OMe), 3.50-3.65 (nH, mb, nPEG + -CH), 3.65-3.73 (2H, m, -CH2 PEG), 4.13-
4.22 (2H, m, -CH2 PEG), 6.86 (1H, s, CH Benzhydryl), 7.20-7.44 (10H, m, ArH) ppm. 
13C NMR (100 MHz, CDCl3, TMS) : 26.43 (-CH2), 27.78 (CH3t-Bu), 28.91, 29.33, 
29.60 (-CH2 + -CH2 + -CH2 succinate), 30.62 (-CH2 succinate), 39.00 (-CH2), 
44.38, 47.36, 47.80, 48.15 (CH2 cyclen), 55.53 (CH2COR), 58.83 (OMe), 61.35 (-CH), 
63.46 (-CH2 PEG), 68.68 (-CH2 PEG), 70.13, 70.27, 70.37 (nPEG), 71.69 (-CH2 
PEG), 78.09 (CH Benzhydryl), 81.91 (C t-Bu), 126.41 (ArH), 128.15 (ArH), 128.54 
(ArH), 139.98 (C ArH), 171.65 (C=O), 172.12 (C=O), 172.54 (C=O t-Bu), 175.10 (C=O 
Benzhydryl) ppm. 
 
DO3A(t-Bu)-A(succinate-PEG550-OMe)HA(Be), 6 
Using a similar procedure to the previously described for compound 5, but with succinate-
PEG550-OMe (324 mg, 498 mol) it was possible to obtain compound 6 (347 mg, 68 %) 
as a yellow solid. 1H NMR (400 MHz, CDCl3, TMS) : 1.18-1.57 (31H, mb, -CH2 + -
CH2 + CH3 t-Bu), 1.61-1.79 (2H, m, -CH2), 1.97-3.31 (28H, mb, CH2 cyclen + -CH2 + 
CH2COR + -CH2 succinate + -CH2 succinate), 3.34 (3H, s, OMe), 3.49-3.65 (nH, m, 
nPEG + -CH), 3.66-3.69 (2H, m, -CH2 PEG), 4.17-4.24 (2H, m, -CH2 PEG), 6.86 
(1H, s, CH Benzhydryl), 7.22-7.39 (10H, m, ArH) ppm. 13C NMR (100 MHz, CDCl3, 
TMS) : 26.39 (-CH2), 27.77 (CH3t-Bu), 28.90, 29.07, 29.63 (-CH2 + -CH2 + -CH2 
succinate), 30.62 (-CH2 succinate), 39.00 (-CH2), 44.29, 47.27, 47.75, 48.10 (CH2 
cyclen), 55.39 (CH2COR), 58.68 (OMe), 61.31 (-CH), 63.59 (-CH2 PEG), 68.88 (-
CH2 PEG), 69.71, 69.92, 70.19 (nPEG), 71.37 (-CH2 PEG), 78.06 (CH Benzhydryl), 
81.92 (C t-Bu), 126.38 (CH), 128.11 (CH), 128.55 (CH), 140.01 (C ArH), 171.71 (C=O), 
172.20 (C=O), 172.84 (C=O t-Bu), 175.11 (C=O Benzhydryl) ppm. 
 
DO3A(t-Bu)-A(succinate-PEG350-Ome)HA(Be), 7 
Using a similar procedure to the previously described for compound 5, but with succinate-
PEG350-OMe (178 mg, 396 mol) it was possible to obtain compound 7 (194 mg, 79 %) 
as a yellow solid. 1H NMR (400 MHz, CDCl3, TMS) : 1.18-1.55 (31H, mb, -CH2 + -
CH2 + CH3t-Bu), 1.64-1.82 (2H, m, -CH2), 1.96-3.32 (28H, mb, CH2 cyclen + -CH2 + 
CH2COR + -CH2 succinate + -CH2 succinate), 3.35 (3H, s, OMe), 3.51-3.65 (nH, m, 
nPEG + -CH), 3.65-3.71 (2H, m, -CH2 PEG), 4.16-4.25 (2H, m, -CH2 PEG), 6.85 
(1H, s, CH Benzhydryl), 7.22-7.43 (10H, m, ArH) ppm. 13C NMR (100 MHz, CDCl3, 
TMS) : 26.45 (-CH2), 27.77 (CH3t-Bu), 28.95, 29.34, 29.62 (-CH2 + -CH2 + -CH2 
succinate), 30.60 (-CH2 succinate), 38.99 (-CH2), 44.30, 47.28, 47.75, 48.13 (CH2 
cyclen), 55.52 (CH2COR), 58.83 (OMe), 61.30 (-CH), 63.45 (-CH2 PEG), 68.68 (-
CH2 PEG), 70.09, 70.26, 70.35 (nPEG), 71.68 (-CH2 PEG), 78.06 (CH Benzhydryl), 
81.90 (C t-Bu), 126.39 (CH), 128.12 (CH), 128.55 (CH), 139.96 (C ArH), 171.65 (C=O), 
172.11 (C=O), 172.56 (C=O t-Bu), 175.08 (C=O Benzhydryl) ppm. 
 
DOTA-A(PEG750)HA, L1 
DO3A(t-Bu)-A(succinate-PEG750-OMe)HA(Be), 5 (480 mg, 292 mol) was dissolved in 
DCM (7 mL) and in TFA (7 mL). The solution was stirred overnight at room temperature 
and concentrated under reduced pressure to give a purple oil. The oil was washed with n-
hexane (2x) and with water (2x) to give a yellow oil. The oil was dissolved in water (70 
mL) and the aqueous solution was washed with DCM (4 x 35 mL) and concentrated under 
reduced pressure to afford compound L1 (400 mg) as a yellow solid in a trifluoroacetate 
salt form. 1H NMR (400 MHz, D2O, TSP) : 1.35-1.93 (6H, mb, -CH2 + -CH2 + -
CH2), 2.50-2.59 (2H, m, -CH2 succinate), 2.67-2.73 (2H, m, -CH2 succinate), 2.88-
4.23 (25H, mb, CH2 cyclen + -CH + -CH2 + CH2CO2H), 3.39 (3H, s, OMe), 3.51-3.73 
(nH, mb, nPEG), 3.77-3.81 (2H, m, -CH2 PEG), 4.25-4.29 (2H, m, -CH2 PEG) ppm. 
13C NMR (100 MHz, D2O, TSP) : 23.63 (-CH2), 28.00 (-CH2), 28.17 (-CH2), 29.43 
(-CH2 succinate), 30.27 (-CH2 succinate), 38.71 (-CH2), 50.47, 51.19, 53.46, 54.35 
(CH2 cyclen), 58.63 (OMe), 60.35 (CH2CO2H),61.17 (-CH), 64.01 (-CH2 PEG), 68.42 
(-CH2 PEG), 68.42, 69.56, 69.62 (nPEG), 70.97 (-CH2 PEG), 168.49 (C=O), 174.41 
(C=O), 174.70 (C=O), 176.79 (C=O) ppm. LRMS (ESI+): calculated for: n = 18 – 
C63H119N5O30 (MH
+) 1426.80, (MH2
2+) 713.90; found 1426.80, (MH+), 713.87 (MH2
2+); 
n = 17 – C61H115N5O29 (MH+) 1382.78, (MH22+) 691.89; found 1382.78, (MH+), 691.86 
(MH2
2+); n = 16 – C59H111N5O28 (MH+) 1338.75, (MH22+) 669.88; found 1338.75, (MH+), 
669.85 (MH2
2+); n = 15 – C57H107N5O27 (MH+) 1294.72, (MH22+) 647.86; found 1294.72, 
(MH+), 647.83 (MH2
2+); n = 14 – C55H103N5O26 (MH+) 1250.70, (MH22+) 625.85; found 
1250.70, (MH+), 625.82 (MH2
2+). 
 
DOTA-A(PEG550)HA, L2 
Using a similar procedure to the previously described for compound L1, but using 
DO3A(t-Bu)-A(succinate-PEG550-OMe)HA(Be)  (347 mg, 241 mol) it was possible to 
obtain compound L2 (313 mg) as a yellow solid in trifluoroacetate salt form. 1H NMR 
(400 MHz, D2O, TSP) : 1.31-1.86 (6H, mb, -CH2 + -CH2 + -CH2), 2.43 (2H, t, 
J=6.6Hz, -CH2 succinate), 2.56 (2H, t, J=6.4Hz, -CH2 succinate), 2.72-4.25 (25H, mb, 
CH2 cyclen) + -CH + -CH2 + CH2CO2H), 3.28 (3H, s, OMe), 3.50-3.70 (nH, mb, nPEG 
+ -CH2 PEG), 4.12-4.17 (2H, m, -CH2 PEG) ppm. 13C NMR (100 MHz, D2O, TSP): 
23.64 (-CH2), 28.08 (-CH2), 28.65 (-CH2), 29.32 (-CH2 succinate), 30.24 (-CH2 
succinate), 38.89 (-CH2), 45.48, 50.65, 53.19, 54.05 (CH2 cyclen), 57.96 (OMe), 60.29 
(CH2CO2H),61.07 (-CH), 63.94 (-CH2 PEG), 68.34 (-CH2 PEG), 69.32, 69.34, 69.56 
(nPEG), 70.89 (-CH2 PEG), 168.72 (C=O), 174.36 (C=O), 174.54 (C=O), 176.79 (C=O) 
ppm. LRMS (ESI+): calculated for: n = 14 – C55H103N5O26 (MNa+) 1272.78, (MNaH2+) 
636.84; found 1272.79, (MNa+), 638.89 (MnaH2+); n = 13 – C53H99N5O25 (MNa+) 
1228.65, (MNaH2+) 614.83; found 1382.76, (MNa+), 614.88 (MNaH2+); n = 12 – 
C51H95N5O24 (MNa
+) 1184.63, (MNaH2+) 592.81; found 1184.73, (MNa+), 592.87 
(MnaH2+); n = 11 – C49H91N5O23 (MNa+) 1140.60, (MnaH2+) 570.80; found 1140.71, 
(MNa+), 570.85 (MnaH2+). 
 
DOTA-A(PEG350)HA, L3 
Using a similar procedure to the previously described for compound L1, but using 
DO3A(t-Bu)-A(succinate-PEG350-OMe)HA(Be)(277 mg, 223 mol)  it was possible to 
obtain compound L3 (252 mg) as a yellow solid in trifluoroacetate salt form. 1H NMR 
(400 MHz, D2O, TSP) : 1.29-1.83 (6H, mb, -CH2 + -CH2 + -CH2), 2.37-2.47 (2H, m, 
-CH2 succinate), 2.48-2.62 (2H, m, -CH2 succinate), 2.75-4.12 (25H, mb, CH2 cyclen 
+ -CH + -CH2 + CH2CO2H), 3.34 (3H, s, OMe), 3.46-3.63 (nH, mb, nPEG), 3.63-3.67 
(2H, m, -CH2 PEG), 4.10-4.14 (2H, m, -CH2 PEG) ppm. 13C NMR (100 MHz, D2O, 
TSP) : 23.66 (-CH2), 28.06 (-CH2), 29.30 (-CH2), 29.37 (-CH2 succinate), 30.22 
(-CH2 succinate), 38.62 (-CH2), 45.36, 50.71, 53.25, 53.95 (CH2 cyclen), 57.93 (OMe), 
60.26 (CH2CO2H),61.08 (-CH), 63.92 (-CH2 PEG), 68.30 (-CH2 PEG), 69.29, 69.31, 
69.45 (nPEG), 70.86 (-CH2PEG), 168.35 (C=O), 174.47 (C=O), 174.64 (C=O), 176.73 
(C=O) ppm. LRMS (ESI+): calculated for: n = 10 – C47H87N5O22 (MH22+) 537.80; found 
537.56, (MH2
2+); n = 9 – C45H83N5O21 (MH22+) 515.78; found 515.34, (MH22+); n = 8 – 
C43H79N5O20 (MH2
2+) 493.77; found 493.28, (MH2
2+); n = 7 – C41H75N5O19 (MH22+) 
471.76; found 471.30 (MH2
2+); n = 6 – C39H71N5O18 (MH22+) 449.75; found 449.25 
(MH2
2+). 
 
 
 
Relaxometric Studies 
 
Sample Preparation 
To an aqueous solution of the ligand, a GdCl3 solution in a 1:1 mole ratio was added 
dropwise (a slight excess of ligand was used). The pH was adjusted to around 4 with the 
addition of a 0.01 M NaOH solution and the solution was stirred for 1 hour at 60 ºC. The 
pH was adjusted to 5 with the addition of a 0.01 M NaOH solution and the solution was 
stirred overnight. The pH was then adjusted to 5.7 and the solution was concentrated 
under reduced pressure. 
In all cases, to the final solution, H2
17O (17O = 20.2 %) was added to obtain a final 2% 17O-
enrichment in order to improve the sensitivity of 17O NMR measurements. The absence 
of free metal was checked with xylenol orange.[34] The final concentration of Gd(III) was 
determined by susceptibility measurements in the presence of t-butanol.[35] The Gd(III) 
concentration in the samples were ≈ 8 mM. 
 
1H NMRD 
Sample tubes with an outer diameter of 5 mm were used for measurements. The proton 
longitudinal relaxation rates (1/T1) for the water nuclear magnetic relaxation dispersion 
profiles (NMRD) were measured at 0.47 T (1H Larmor frequency: 20 MHz), 0.70 T 
(30 MHz), 0.94 T (40 MHz), 1.41 T (60 MHz), 2.35 T (100 MHz), 4.7 T (200 MHz) and 
9.4 T (400 MHz). The longitudinal relaxation rates of three chelates with known 
concentration were measured at two different temperatures (25 and 37 ºC). Acidified 
water (pH = 3.0) was used as an external reference. The relaxivities r1 (mM
-1.s-1) were 
calculated using equation 1 using diamagnetic relaxation contributions 1/T1(d) of 0.31 s
-1 
(400 MHz) / 0.40 s-1 (20 MHz) for 25 ºC and 0.25 s-1 (400 MHz) / 0.29 s-1 (20 MHz) for 
37 ºC, respectively. 
 
𝑟1 =
1
[𝐺𝑑(𝐼𝐼𝐼)]
(
1
𝑇1
−
1
𝑇1(d)
) , with [Gd(III)] in mM (1) 
 
For full equations see Supplementary Information (SI). 
 
 
 
17O NMR 
The samples were sealed in glass spheres adapted for 10 mm NMR tubes, in order to 
avoid susceptibility corrections to the chemical shifts.[36] Variable-temperature 17O 
measurements were performed at 9.4 T (17O Larmor frequency: 54.3 MHz). The 
longitudinal (1/T1) and transverse (1/T2) relaxation rates were measured using the 
inversion-recovery[37] and the Carr–Purcell–Meiboom–Gill[38] pulse sequences, 
respectively, and chemical shifts () were measured at 12 different temperatures in the 
range from 5 to 65 °C. The reduced relaxation rates T1r and T2r and the reduced chemical 
shift differences r, with respect to a pH 3.0 water reference (2% 17O-enrichment), were 
calculated using equations 2 to 4. The number of water molecules in the inner sphere of 
the complex q was fixed to one. 
 
1
𝑇ir
=
1
𝑃𝑀
(
1
𝑇i
−
1
𝑇i
ref) , where i = 1, 2 (2) 
 
∆𝜔𝑟 =
1
𝑃𝑀
(𝜔 − 𝜔ref) (3) 
 
𝑃M =
𝑞[M(n)]
55.56
 (4) 
 
For full equations see Supplementary Information (SI) 
 
Data Analysis 
For fits of the 1H NMRD and 17O NMR data, a Solomon–Bloembergen-based theory was 
used[36b, 39]  supplemented with the Lipari–Szabo free-model approach for the internal 
rotation.[40] The simultaneous fits were performed using Visualiseur/Optimiseur[41] 
running on a MATLAB® 8.0 (R2012b) platform. 
 
 
 
 
 
 
 
1H NMR studies of paramagnetic lanthanide DOTA-A(PEG750)HA chelates 
 
Samples preparation 
To an aqueous solution of the ligand, the corresponding LnCl3 solution in 1:1 mole ratio 
was added dropwise (a slight excess of ligand was used: 5%). The pH was adjusted to 
around 4 with the addition of a 0.01 M NaOH solution and the solution was stirred for 1 
hour at 60 ºC. The pH was adjusted to 5 with the addition of a 0.01 M NaOH solution and 
the solution was stirred overnight. The pH was then adjusted to 7 and the solution was 
concentrated under reduced pressure. 
 
Measurements 
The solutions were prepared by dissolving the respective chelate in D2O (700 L). The 
proton spectra of the Pr(III), Nd(III), Sm(III), Eu(III) and Yb(III) chelates were obtained 
at 7, 25, 40 and 60 ºC. The 1H NMR spectra were recorded on a Varian Unity Plus 300 
spectrometer, operating at 299.938 MHz. 
 
Abbreviations 
 
Be Benzhydryl 
CA Contrast agent 
Cyclen 1,4,7,10-tetraazacyclododecane 
DCM Dichloromethane 
DEPT Distortionless enhancement by polarization transfer 
DIPEA N,N-Diisopropylethylamine 
DMSO Dimethyl sulfoxide 
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTA-AHA 1,4,7,10-Tetraazacyclododecane-1-[(6-amino)hexanoic]-
4,7,10-triacetic acid 
DOTA-A(PEG750)HA 1,4,7,10-Tetraazacyclododecane-1-[6-amino(MeO-PEG750-
succinate)]hexanoic-4,7,10-triacetic acid 
DOTA-A(PEG550)HA 1,4,7,10-Tetraazacyclododecane-1-[6-amino(MeO-PEG550-
succinate)]hexanoic-4,7,10-triacetic acid 
DOTA-A(PEG350)HA 1,4,7,10-Tetraazacyclododecane-1-[6-amino(MeO-PEG350-
succinate)]hexanoic-4,7,10-triacetic acid 
DOTASA 1,4,7,10-Tetraazacyclododecane-1-succinic acid-4,7,10-
triacetic acid 
ESI Electrospray ionization 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
HMBC Heteronuclear multiple bond correlation 
HOBt 1-Hydroxybenzotriazole 
HOPO Hetero-tripodal hydroxypyridonate 
HSA Human serum albumin 
HSQC Heteronuclear Single Quantum Coherence 
LRMS Low resolution mass spectrometry 
MeCN Acetonitrile 
MRI Magnetic resonance imaging 
NMR Nuclear magnetic resonance 
NMRD Nuclear magnetic relaxation dispersion 
PEG Poly(ethylene) glycol 
SD Standard deviation 
TFA Trifluoroacetic acid 
TMS Tetramethylsilane 
TSP 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt 
TLC Thin layer chromatography 
t-Bu tert-Butyl 
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